Author Archive: BIOtechNOW Editor

FDA Check-Up: Drug Development and Manufacturing Challenges

Paul Hastings

I have over 27 years of experience in the biotechnology and pharmaceutical industry. My current company, OncoMed Pharmaceuticals, is working at the cutting edge of oncology research, focused on antibodies that target a specific set of cells within tumors, known as tumor initiating cells, that drive the growth of the tumor and can differentiate into various cell types within the tumor. Currently, we have five products in clinical development in over 13 completed or ongoing Read More >

Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

The Arrival of Actionable Personalized Medicine

kevin-davies115-76

The pace of implementation of next-generation sequencing (NGS) in a clinical context, which almost rivals the development of the technology over the past decade, is driving the cost of a full genome sequence down to just a few thousand dollars. Diagnostic companies and medical centers are now routinely offering comprehensive genome analysis, as evidenced by the recent report from Baylor College of Medicine in the New England Journal of Medicine on the first 250 patients Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

New Cancer Treatments Seek to Give the Immune System Superpowers

Wendy Selig 2013

Melanoma is scary. It is aggressive, spreads quickly to far-away organs with the stealth and cunning of the most adept villain, and it is increasingly striking young people-it is now the most common form of cancer diagnosed in women 25-29. But the “good guys” are fighting back with increasing success. As the CEO of the Melanoma Research Alliance (MRA), a patient-focused, science-based organization dedicated to fighting this deadly skin cancer, I see signs every day Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , ,

JOBS Act Deconstructed: Regulation A

More than 40 biotech companies have gone public using provisions made available to emerging growth companies through the JOBS Act.  BIOtechNOW’s JOBS Act Deconstructed series will explore why it has had such an impact on biotech offerings and how emerging companies can leverage the new law to their best advantage. In a nutshell: The JOBS Act directs the SEC to create a new class of securities modeled after those eligible for the existing exemption under SEC Read More >

Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , ,

Fighting Blindness through Sound Investments in Research

Bill2_115x76

Since 1971, the Foundation Fighting Blindness has raised more than half a billion dollars in support of its mission to put an end to retinal diseases. Those diseases affect more than 10 million Americans at risk of vision impairment, legal blindness or total blindness. Because age-related macular degeneration (AMD), one of the diseases we target, is the leading cause of blindness in people over 55, and because the Baby Boomer population is aging, that number Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,